Quantcast

NanoSonic Products and Florida Biologix have signed a contract for the formulation and fill of the sterile liquid form of its Trappsol Cyclo product, an FDA and EMEA designated orphan drug for the treatment of Niemann Pick Type-C disease, also known as Childhood Alzheimer’s, which affects children and adults and manifests with progressive neurological symptoms. Trappsol Cyclo is currently being administered in the U.S. under a compassionate use IND.

Florida Biologix, with a proven track record of biopharmaceutical cGMP manufacturing campaigns and drug product fills for US and European clinical trials, will formulate, fill, label, test and package 3,000 vials of this exciting therapy for patients with this devastating disease.

Leave a Reply

Your email address will not be published. Required fields are marked *

*